JENAVALVE ANNOUNCES FIRST IMPLANTATIONS OF TRANSAPICAL TAVI SYSTEM IN FRANCE

Company Continues to Expand Commercialization of Second-Generation Device in Europe

Wilmington, Delaware and Munich, Germany – December 17, 2013 – JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, announced today that it has successfully completed the first two implantations of its second-generation transapical JenaValve TAVI system in France.

The implantations were performed by cardiac surgeon Mauro Romano, M.D., and interventional cardiologist Thomas Hovasse M.D. at the Hôpital Privé Jacques Cartier, Massy, France. PD Sabine Bleiziffer, M.D., Senior Cardiac Surgeon at the German Heart Center Munich, Germany, served as proctor to support the implantations.

"We treated two patients with the transapical JenaValve, one female patient with a leading aortic insufficiency and one male patient with a severely calcified aortic valve. In both we achieved very good results, without paravalvular leakage rate and absence of significant gradients," said Dr. Romano. "JenaValve's second-generation TAVI system showed in these two cases that the whole range of aortic valve diseases can be treated thanks to the unique clipping and fixation mechanism."

"In addition to the mentioned clipping mechanism, the possibility to place the JenaValve anatomically correct is surely the feature that confirms JenaValve´s approach as a 2nd generation TAVI device, " Dr. Romano added. "So called "feelers" guide the prosthesis into the right position so that it is placed in the correct height and with commissural alignment. Low pacemaker rates and no coronary obstructions in JenaValve´s post market registry JUPITER confirm the value of this anatomically correct positioning."

Helmut J. Straubinger, CEO of JenaValve Technology, stated that the first two JenaValve implantations in France confirm ones more the company´s approach to make its TAVI system available for patients in all European countries.

"We are really proud that we could show the advantages of our transapical TAVI device for the first time in France. Thanks to the unique features our system offers, we can treat the broadest range of TAVI patients and create so an additional value for both, the patients and our customers."

About TAVI

Transcatheter aortic valve implantation (TAVI) systems have already yielded nearly $1 billion in revenues worldwide and the market is expected to grow to over $3 billion in 2016[1]. Clinicians are now focused increasingly on TAVI technical and procedural refinements and advancements found in second-generation products such as JenaValve's that address and resolve issues including ease of implantation, the need for post-procedure pacemaker implantation and post-implant paravalvular leakage.

About the JenaValve™ TAVI System

The JenaValve is a true second-generation catheter-based aortic valve implantation system engineered

and manufactured to the highest quality standards. The JenaValve transapical TAVI system is currently being sold in Europe. The First-in-man trail for the company's transfemoral TAVI system started in December 2013 and is anticipated to be commercial available end of 2014.

- **The JenaValve prosthesis** consists of a natural aortic porcine root bioprosthesis fitted with an outer porcine pericardial patch, a so-called skirt, before being sewn onto a Nitinol self-expanding stent. The high-quality bioprosthesis is durable, ensuring long-term aortic valve function.

- **JenaValve's unique "3-feeler element"** allows the clinician to accurately position the prosthesis in the anatomically correct position during implantation thus ensuring to achieve the correct implantation height and commissural alignment within the patient's native valve.

- **JenaClip™ anchoring and clipping mechanism** allows the valve to be clipped onto the patient's native valve leaflets enabling the JenaValve to be firmly anchored in the correct anatomical position and provide active fixation and resistance to migration independent from the calcification level of the native valve.

- **The JenaValve implantation** is conducted on the beating heart. Hemodynamic flow is maintained without cardiac arrest and rapid pacing is not required during the procedure. The low profile of the stent prosthesis ensures open flow to the coronaries after the implantation. The JenaValve is available in three sizes, 23mm, 25mm and 27mm, covering aortic valve annuli from 21mm to 27mm.

- **JenaValve is retrievable and repositionable** thereby contributing to a successful procedure and confidence of the clinician.

About JenaValve Technology, Inc.

JenaValve Technology, Inc., a U.S. corporation with primary operations in Munich, Germany, develops, manufactures and markets transcatheter aortic valve implantation (TAVI) systems to treat patients suffering from aortic valve disease. JenaValve was founded in 2006 by cardiologists and inventors Prof. Hans R. Figulla, M.D. and Prof. Markus Ferrari, M.D.. The Company's transapical TAVI system is CE marked and currently marketed in Europe and other markets worldwide. JenaValve is backed by world-class U.S., European and Asian investors. Additional information is available at www.jenavalve.com

European Contact: JenaValve Technology Inc. and JenaValve Technology, GmbH, Munich (Germany) +49 895 527 9080 or info@jenavalve.de

U.S. Contact: Rene Caron, Allen & Caron Inc. +1-949 474 4300 or rene@allencaron.com

1) Goldman Sachs Global Investment Research